Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Leadership is about driving change at scale and requires engaging both hearts and minds. Sally Susman, Executive Vice President and Chief Corporate Affairs Officer at Pfizer, provides insights ...

BenchSci, a world leader in AI solutions for preclinical research and drug discovery, today announced that Mikael Dolsten, M.D., Ph.D., has joined its board of directors.

Two former Pfizer executives published a statement saying they support management as it gets pressured for changes by activist investor Starboard Value. The ex-Pfizer executives, Ian Read and ...

Pfizer is making these changes in preparation for integrating Seagen once the $43 billion merger closes, expected in late 2023 or early 2024. For now, the two companies are operating independently ...

Former Pfizer Inc PFE CEO Ian Read and ex-CFO Frank D’Amelio have decided to distance themselves from the activist campaign led by Starboard Value at the pharmaceutical giant.

Pfizer told U.S. District Judge Jennifer Rochon of Manhattan, in a brief opposing Do No Harm’s bid for a preliminary injunction, that the law permits the use of racial selection criteria when it ...